Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Rare Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Rare Neoplasm

Cancer Family

Rare Neoplasm

CI-CAN-00000048Explore in graph →

Non-malignant116 active trials3 approved drugs7 evidence items

NCIt: C7201

Overview
Statistics
Survival
Genomics3
Variants & evidence7
Drugs4
Trials361
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (8)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–8 of 8 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
· N Engl J Med · 2016 · PMID 27355533 · validated civic_curation pubmed
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.
· Leukemia · 2016 · PMID 26464169 · validated civic_curation pubmed
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.Retracted
· N Engl J Med · 2015 · PMID 26287849 · validated civic_curation pubmed
Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.
· J Clin Oncol · 2019 · PMID 31513482 · validated civic_curation pubmed
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.
· Leuk Res · 2009 · PMID 19193436 · validated civic_curation pubmed
An 8-year-old girl with secondary histiocytic sarcoma with BRAFV600 mutation following T-cell acute lymphoblastic leukemia demonstrating stable disease for 3 years on dabrafenib and trametinib - a case report and literature review.
· BMC Pediatr · 2025 · PMID 40057687 · validated civic_curation pubmed
Eli et al. Nature 2019
· 2019 · PMID 30867592 · validated cbioportal_study

Showing 1–8 of 8 publications

Cyrta et al. 2022 Cold Spring Harb Mol Case Stud 8: a006227

· 2022 · PMID 36577525 · validated cbioportal_study pubmed